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Abstract
Aims/hypothesis The aims of this study were to provide a
contemporary picture of mortality and causes of death in
Europe following a diagnosis of type 1 diabetes made before
the 15th birthday, and to examine excess mortality by country
for possible links to incidence level or national prosperity.
Methods Thirteen population-based EURODIAB registers
in 12 countries followed-up 28,887 children diagnosed
since 1989, either by record linkage to population registers
or through contact with doctors providing care.
Results There were 141 deaths in the cohort during 219,061
person-years of follow-up compared with 69.1 deaths
expected from national mortality rates, a standardised
mortality ratio (SMR) of 2.0 (95% CI 1.7–2.4). The SMR
varied from 0 to 4.7 between countries, but showed little
relationship with the country’s incidence rate or gross
domestic product (US$ per capita). The SMR did not
change significantly with attained age, calendar period or
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time since diagnosis. The female SMR (2.7; 95% CI 2.0–
3.5) was greater than the male SMR (1.8; 95% CI 1.4–2.2),
although absolute numbers of excess deaths were similar in
the two sexes. One-third of deaths were classified as
directly attributable to diabetes (many with mention of
ketoacidosis) and half were unrelated to diabetes. There
was a non-significant excess of accidental/violent deaths
(48 observed vs 40.7 expected; SMR 1.2; 95% CI 0.9–1.6)
but little excess in suicides (11 observed, 10.2 expected;
SMR 1.1; 95% CI 0.5–1.9).
Conclusions/interpretation Before the onset of late compli-
cations, significant excess mortality existed following the
diagnosis of type 1 diabetes in childhood, even in recent
years. Variation between countries in this excess could not
be explained.
Keywords Cause of death . Cohort .Mortality .
Standardised mortality ratio . Type 1 diabetes
Abbreviations
SMR standardised mortality ratio
Introduction
Although many studies have described mortality follow-up
of population-based cohorts of children with type 1
diabetes, few studies have compared results from dif<
ferent countries. One involving Japan, Israel, Finland and
Pennsylvania, USA [1], and another from Finland, Estonia
and Lithuania [2] showed large variations between
countries in mortality relative to that expected from national
rates. The aims of the present study were: (1) to provide a
contemporary picture of mortality in childhood-onset type 1
diabetes in Europe in the years after diagnosis but before
the onset of cardiovascular and renal complications; (2) to
present each country’s mortality relative to that expected
from national rates; (3) to examine excess mortality by age,
sex, calendar period and time since diagnosis; and (4) to
assess possible links between a country’s excess mortality
and its incidence level or a measure of its national
prosperity.
Methods
The case inclusion criterion was that used for the EURO-
DIAB registers [3] (new diagnosis of type 1 [insulin-
dependent] diabetes mellitus among children aged under
15 years). Four centres (Denmark, Finland, Norway and
Sweden) extended coverage of their EURODIAB cohorts to
include national data for cases diagnosed since 1989. Small
numbers of deaths at onset were recorded in a number of
centres, but since the completeness of ascertainment of such
deaths is uncertain and could vary between countries, onset
deaths are not considered in this report.
Most centres obtained follow-up passively by linking the
records of diabetic children to some form of official
population register. Four centres (Bulgaria, Lithuania,
Germany and Iceland) actively followed-up patients by
tracing them through clinics or family doctors. These
centres were urged to use multiple sources of ascertainment
to obtain as complete a follow-up as possible, since deaths
among untraced children could easily introduce bias.
Record linkage follow-up ended on the date at which
linkage with the population register took place, allowing for
some delay in the updating of deaths on the population
register, if appropriate. Individual follow-up ended on the
date at which each patient’s vital status (living or dead) was
determined.
As much information as possible about each death was
obtained (date, place, circumstances, recent medical history,
autopsy report, hospital notes, registered causes of death,
and underlying cause), but the amount of information
available varied considerably from centre to centre. All
causes of death were as coded or translated to the WHO
International Classification of Diseases revision 10, the
revision in use for the later part of the follow-up period. A
panel of study participants used available information to
classify deaths into one of four categories: (1) diabetes-
related; (2) uncertain relationship to diabetes; (3) unrelated
to diabetes; and (4) unknown/insufficient information.
For nine deaths the information on the cause was
sufficient to identify the disease as not being type 1
diabetes but diabetes secondary to another cause, and these
deaths were excluded from the study.
Observed numbers of deaths (O) in each cohort were
compared with national mortality rates [4] using person-
years at risk analysis. This involved the calculation of
expected numbers of deaths (E) in the cohort given the
background population mortality rates and taking account
of each child’s sex, age (grouped as 0–4 years, 5–9 years,
10–14 years, 15–19 years, 20+ years), and calendar period
(1989–1993, 1994–1998 and 1999–) during follow-up.
Standardised mortality ratios (SMR = O/E) were obtained
and 95% confidence limits derived using the Poisson
distribution. Poisson regression [5] was used to investigate
associations between a country’s SMR and its incidence
rate in 1989–1998 [6] and between a country’s SMR and its
gross domestic product (US$ per capita) in 1994 [7].
Poisson regression was also used to compare SMRs by age-
group, calendar period, time since diagnosis and sex whilst
stratifying by centre.
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Results
Thirteen EURODIAB centres participated in the study,
following up 28,887 children diagnosed since 1989 for an
average of 7.6 years (Table 1). There were 141 deaths during
the 219,061 person-years of follow up (0.64 deaths per 1,000
person-years) compared with 69.1 deaths expected from
national mortality rates. The SMR was 2.0 and varied from
0 to 4.7 between centres. Poisson regression analysis
confirmed that there was statistically significant heterogeneity
in SMR between centres (χ2=36.7, df=12; p=0.0002).
However, neither incidence rate (χ2=0.02, df=1; p=0.89)
nor gross domestic product (χ2=0.48, df=1; p=0.49) were
able to explain this heterogeneity (Electronic supplementary
material Fig. 1).
Findings obtained by aggregating results over centres are
presented in Table 2. The SMR was not found to differ
significantly by attained age, calendar period or time since
diagnosis. However, there was evidence that the SMR was
higher in females than in males (χ2=5.68, df=1; p=0.02).
Sufficient information about the causes of death was
available to classify 134 of the 141 deaths. Of these, 47
(35%) were assessed as being directly attributable to
diabetes, including 27 with mention of diabetic ketoacido-
sis; 71 (53%) were assessed as unrelated to diabetes; and
for the remaining 16 (12%) the role played by diabetes was
uncertain. Five deaths were ascribed directly to hypogly-
caemia. In seven deaths the patient was found dead in bed
with no obvious cause, but an autopsy was not always
performed and only three fulfilled strict criteria for the so-
called dead-in-bed syndrome [8]. The number of deaths
from accidents and violence, including suicides, was only
marginally more than the number expected from national
rates (48 observed vs 40.7 expected; SMR 1.2; 95% CI
0.9–1.6). The number of deaths from suicide was similar to
that expected from national rates (11 observed vs 10.2
expected; SMR 1.1; 95% CI 0.5–1.9).
Discussion
Our study demonstrates that significant excess mortality
persists in European countries in the years following the
diagnosis of type 1 diabetes in childhood but before the
onset of late complications. Variation between countries is
Table 2 Follow-up results aggregated over 13 EURODIAB centres
Person-years
(thousands)
Observed
deaths (O)
Expected
deaths (E)
SMR=O/E
(95% CI)
Attained age (years)
0–4 11.6 5 3.2 1.6 (0.5–3.6)
5–9 46.0 14 6.7 2.1 (1.1–3.5)
10–14 76.0 27 12.1 2.2 (1.5–3.2)
15–19 59.1 56 28.4 2.0 (1.5–2.6)
20+ 26.5 39 18.7 2.1 (1.5–2.9)
Calendar period
1989–1993 21.7 13 5.8 2.2 (1.2–3.8)
1994–1998 70.2 34 19.4 1.8 (1.2–2.5)
1999– 127.2 94 43.9 2.1 (1.7–2.6)
Time since diagnosis (years)
0–4 124.3 55 28.8 1.9 (1.4–2.5)
5–9 70.7 56 26.6 2.1 (1.6–2.7)
10+ 24.1 30 13.8 2.2 (1.5–3.1)
Sex
Male 114.9 86 48.8 1.8 (1.4–2.2)
Female 104.2 55 20.4 2.7 (2.0–3.5)
Table 1 Summary of mortality follow-up results in 13 EURODIAB centres ordered by increasing incidence rate
Centre Cases Registration End of follow-up Lost to
follow-up
Person-years Observed
deaths (O)
Expected
deaths (E)
SMR (O/E)
(95% CI)
Lithuania 1,006 1989–2003 Jan 2004 to Feb 2005 11a 7,568 15 5.2 2.9 (1.6–4.7)
Bulgaria (Eastern) 443 1989–1999 Mar 2004 8 4,069 10 2.1 4.7 (2.3–8.7)
Hungary (ex. Budapest) 1,968 1989–2002 Dec 2002 9 13,341 5 4.5 1.1 (0.4–2.6)
Austria 1,989 1989–2002 Dec 2003 0 14,744 6 4.9 1.2 (0.5–2.6)
Spain (Catalonia) 1,809 1989–2002 Dec 2005 0 18,736 3 7.1 0.4 (0.1–1.2)
Germany (Dusseldorf) 757 1989–2001 Sep 2002 to Sep 2005 102 5,027 4 1.4 2.8 (0.8–7.2)
Iceland 151 1989–2004 Dec 2005 0 1,311 0 0.5 0.0 (0.0–6.9)
Denmark 2,285 1989–2002 Dec 2002 27 13,100 10 3.3 3.0 (1.5–5.6)
UK (Leeds) 2,248 1989–2004 Dec 2005 1 18,567 19 5.3 4.2 (2.2–5.6)
Norway 3,130 1989–2003 Dec 2005 22a 27,673 19 9.5 2.0 (1.2–3.1)
UK (Northern Ireland) 1,310 1989–2002 Dec 2003 53a 9,453 9 3.2 2.9 (1.3–5.4)
Sweden 7,095 1989–2002 Dec 2002 0 45,160 14 9.7 1.4 (0.8–2.4)
Finland 4,696 1989–2000 Dec 2003 0 40,312 27 12.4 2.3 (1.4–3.2)
Total 28,887 219,061 141 69.1 2.0 (1.7–2.4)
aMigrants
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evident in this excess mortality, but our results do not
suggest that it can be explained by a country’s incidence
rate or gross domestic product.
The use of geographically based registers with high
levels of ascertainment should ensure the representativeness
of the study cohorts, but we cannot be certain that the
different approaches used by the various centres have not
resulted in follow-up of varying quality and completeness.
Despite the large overall number in the cohorts, the low
rates of mortality result in relatively few deaths and may
limit the power of our analysis to identify determinants of
the country-to-country differences in SMR. Although we
did find a significant excess in SMR among women
compared with men (2.7 vs 1.8), it is worth remarking
that, in absolute terms, the numbers of excess deaths in men
(37.2) and women (34.6) were similar.
The rather limited and variable amount of information
available about deaths in the different countries made detailed
analysis of causes difficult. We chose a simple four-category
classification with a consensus panel review of the less
straightforward cases. The number of deaths assessed as being
unrelated to diabetes (71) corresponds closely with the
number of deaths expected in the cohorts from national
mortality rates (69.1). Most of the excess of deaths were
directly attributable to diabetes, and in the majority of such
deaths there was mention of diabetic ketoacidosis. The
publication of a consensus statement is a welcome step
towards reducing the number of such deaths in the future [9].
Despite the difficulty in establishing low blood glucose
levels post mortem, a few deaths could be ascribed to
hypoglycaemia. In addition, some deaths were compatible
with the dead-in-bed syndrome, which is thought to be
caused by hypoglycaemia-induced cardiac arrhythmia [8].
In the words of a recent editorial, the harvest of sorrow
goes on [10]. Before the onset of late complications, sig-
nificant excess mortality following the diagnosis of type 1
diabetes in childhood still occurs in most European
countries. Variation among countries in this excess mortal-
ity was not explained by how common the disease was in
the country or the country’s wealth.
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